Objective: Previously, we observed an association between family history of type 1 diabetes and development of non-insulin-dependent diabetes. The aims of this study were to assess whether type 1 diabetes susceptibility gene variants explain this association and investigate the effect of the variants on insulin secretion and presence of glutamic acid decarboxylase autoantibodies (GADA) in nondiabetic adults. Design and methods: Polymorphisms in INS (rs689), PTPN22 (rs2476601), CTLA4 (rs3087243), and the HLA-DQA1-DQB1 regions (rs2187668 and rs7454108 tagging HLA-DQ2.5 and HLA-DQ8 respectively) were genotyped in the Botnia Prospective Study (nZ2764), in which initially nondiabetic participants were followed for a mean of 8.1 years. Results: The variants did not explain the association between family history of type 1 diabetes and development of non-insulin-dependent diabetes. In these nondiabetic adults, HLA-DQ and PTPN22 risk genotypes were associated with GADA (HLA-DQ2.5/HLA-DQ8 or HLA-DQ8: OR (95% CI): 1.7 (1.3-2.3), PZ0.0004; PTPN22 CT/TT: OR: 1.6 (1.2-2.2), PZ0.003; P values were adjusted for sex, age, BMI, and follow-up time). A higher genetic risk score was associated with lower insulin secretion (insulinogenic index: 13.27 (16.27) vs 12.69 (15.27) vs 10.98 (13.06), PZ0.02) and better insulin sensitivity index (risk score of 0-1 vs 2-3 vs 4-6: 142 (111) vs 144 (118) vs 157 (127), PZ0.01) at baseline and a poorer capacity to compensate for the increased insulin demand after follow-up. Conclusions: In nondiabetic adults, HLA-DQ2.5/HLA-DQ8 and PTPN22 CT/TT genotypes were associated with GADA.
Introduction
Diabetes is a complex disease with two main subtypes, autoimmune insulin-dependent type 1 diabetes and mainly non-insulin-dependent type 2 diabetes. Both major subtypes have genetic and environmental risk factors. Among the factors shown to increase the risk of developing non-insulin-dependent diabetes, at least in Northern Europe, are glutamic acid decarboxylase autoantibodies (GADA) and family history of type 1 diabetes (1, 2) . With respect to family history of type 1 diabetes, the association was not restricted to GADA-positive patients developing diabetes, i.e. latent autoimmune diabetes in adults (LADA). These findings suggest a possible overlap between insulin-and noninsulin-dependent diabetes, which is further supported by the clustering of the two diabetes subtypes in the same families (3, 4, 5) . However, no common susceptibility variants contributing to both subtypes have been identified, except possibly in GLIS3 (6, 7, 8) . The majority of identified susceptibility gene variants for type 2 diabetes affect b-cell function (9) , underlining the importance of reduced insulin secretory capacity in disease development. In nondiabetic adults, a reduced maximal insulin secretory capacity is associated with GADA, which indicates that these autoantibodies could be markers of a subclinical autoimmune process affecting b-cell function (10) . This notion is supported by the fact that patients with GADA-positive type 2 diabetes (LADA) are especially prone to progression to insulin deficiency (11, 12, 13) . In patients with type 1 diabetes, autoantibody positivity is associated with HLA genotypes (14, 15) . However, no studies have examined the genetic predisposition for these autoantibodies in a large sample of nondiabetic adults.
In the Botnia Prospective Study, we assessed whether validated type 1 diabetes risk variants in HLA-DQA1-DQB1, protein tyrosine phosphatase, nonreceptor type 22 (PTPN22), INS, and cytotoxic T-lymphocyteassociated protein 4 (CTLA4) explain the previously observed association between family history of type 1 diabetes and development of non-insulin-dependent diabetes and whether these variants are associated with GADA positivity and changes in insulin secretion in nondiabetic adults.
Subjects and methods
In the Botnia Prospective Study, we followed 2764 initially nondiabetic relatives or spouses of type 2 diabetic patients (2, 16, 17) . Information about firstto third-degree family history of type 1 and type 2 diabetes was retrieved from questionnaires or clinical investigation of the relatives. Serum C-peptide, triglyceride, total cholesterol, and HDL were measured at fasting and serum insulin as well as plasma glucose at K5, 0, 30, 60, and 120 min during a 75 g oral glucose tolerance test (OGTT). GADA and insulinoma antigen 2 autoantibody (IA-2A) measurements were available for 2764 (100%) and 2298 (83%) subjects respectively (for details, see (2) ). At baseline, 236 (8.5%) were GADA positive and 53 became positive during the follow-up (2). Only ten subjects were IA-2A positive at any time, precluding their separate analysis. The study was approved by the local ethics committee.
Insulin sensitivity was evaluated using the homeostatic model assessment of basal insulin resistance (HOMA IR ) and the insulin sensitivity index (ISI) derived from the OGTT data (18) . b-Cell function was assessed as an insulinogenic index and corrected insulin response during the first 30 min of the OGTT (19) . The PTPN22 rs2476601, INS rs689, CTLA4 rs3087243, and HLA-DQA1-DQB1 rs2187668 and rs7454108 (tagging DQA1*05/DQB1*02 (DQ2.5) and DQA1*03/DQB1*0302 (DQ8) respectively (20) 
Results

Development of diabetes
During a mean (GS.D.) follow-up time of 8.1G3.6 years, 170 subjects (6.2%) developed diabetes. Of these, 167 developed non-insulin-dependent diabetes (GADAnegative type 2 diabetes: nZ133; GADA-positive LADA: nZ34). Three patients were diagnosed with type 1 diabetes.
A Cox regression analysis, including known risk factors for the development of type 2 diabetes and type 1 diabetes susceptibility variants, showed that the association between family history of type 1 diabetes and noninsulin-dependent diabetes was independent of the variants (Table 1) . Substituting individual variants with the genetic risk score gave the same result. 
GAD autoantibodies
HLA and PTPN22 risk genotypes were associated with GADA in these initially nondiabetic subjects (HLA-DQ2.5/HLA-DQ8 or HLA-DQ8: OR (95% CI): 1.7 (1.3-2.3), PZ0.0004; PTPN22 CT/TT: OR: 1.6 (1.2-2.2), PZ0.003, P values were adjusted for sex, age, BMI, and follow-up time). The HLA association was mainly driven by co-occurrence of DQ2.5 and DQ8, whereas no association was observed for DQ2.5 alone (Table 2) . Excluding subjects who developed diabetes during follow-up gave the same results (data not shown). Among the GADA-positive subjects, the frequency of subjects with a high GADA level was increased in HLA, PTPN22, and INS risk genotype carriers, however, only significantly for HLA-DQ2.5/HLA-DQ8 (PZ0.004, Table 2 ). Figure 1 shows the prevalence of GADA in groups stratified by genotype and presence of family history of type 1 diabetes. With respect to HLA, PTPN22, and INS, the highest prevalence of GADA-positive subjects was observed in the group having both risk genotype and family history (HLA: OR: 2.3 (1.5-3.6), PZ0.0002; PTPN22: OR: 3.1 (1.9-5.0), PZ7.4! 10 K6 ; INS: OR: 1.9 (1.3-2.9), PZ0.001; Fig. 1 and Table 2 ). Regardless of family history, CTLA4 was not associated with GADA.
Quantitative traits
At baseline, the gene variants were associated with higher insulin sensitivity index (ISI) (genetic risk score of 0-1 vs 2-3 vs 4-6: 142 (111) vs 144 (118) vs 157 (127), PZ0.01) and reduced insulin secretion (insulinogenic index: 13.27 (16.27) vs 12.69 (15.27) vs 10.98 (13.06), PZ0.02) ( Table 3) . During follow-up, BMI increased and insulin sensitivity decreased irrespective of the risk score ( Fig. 2A and B) . Subjects with a high risk score were unable to compensate for this by increasing insulin secretion to the same level as subjects with a low score (Fig. 2C) .
Discussion
We evaluated the effect of type 1 diabetes susceptibility gene variants in the Botnia Prospective Study. The main findings in these nondiabetic adults were the association of HLA-DQ2.5/HLA-DQ8 and PTPN22 CT/TT with GADA positivity, as well as a possible effect of the investigated variants on insulin secretion. However, the presence of these type 1 diabetes susceptibility genotypes did not explain the observed increased risk of non-insulin-dependent diabetes associated with family history of type 1 diabetes.
Our study adds to the knowledge of genetics of autoimmunity. HLA-DQ2.5/HLA-DQ8 and PTPN22 CT/TT were associated with expression of GADA in this nondiabetic population. For both HLA and PTPN22, the highest prevalence of GADA was observed in subjects carrying both the risk genotypes and having family history of type 1 diabetes. Previously, association between GADA and HLA-DQ2/HLA-DQ8 or HLA-DQ8 has been observed in healthy children (21, 22, 23) and adult-onset type 1 diabetic patients (21, 24) but not in children or adolescents with type 1 diabetes, in whom GADA is associated with DQ2 (14, 24, 25, 26) . Association between PTPN22 and GADA is reported in patients with long disease duration (27) but not in type 1 diabetic children (15, 28) . Of note, the frequencies of HLA and PTPN22 risk genotypes in the GADA-positive nondiabetic subjects were practically identical to the frequencies in GADA-positive LADA patients (29) . This could indicate that the gene variants affect the autoimmune process giving rise to the antibodies, but that additional factors are necessary to cause development of diabetes. The INS (K23Hph1) variant was associated with GADA only in subjects with family history of type 1 diabetes. In type 1 diabetic patients, one study has reported an association with GADA (30), whereas the majority have found no association (15, 26, 31) . Based on our results, the CTLA4 (CT60) variant does not seem to play a major role in the expression of GADA in nondiabetic adults. In type 1 diabetic patients, the conclusion is similar (15, 26, 31, 32) .
The investigated variants did not explain the risk of diabetes conferred by GADA and family history of type 1 diabetes. The Botnia Study is the largest reported prospective study including data on family history of diabetes and autoantibody measurements. However, the number of subjects who developed diabetes was low and the main limitation of this study is the sample size, which should be taken into account when interpreting the findings. Although a large cross-sectional study sample would have been more powerful to detect weak genetic associations, a prospective study design is less prone to selection as well as recall bias where disease status can influence the reporting of family history (33) . Another limitation of our study was the inability to analyze the effect of pure type 1 diabetes family history due to commonness of type 2 diabetes in the population. It is possible that genes not associated with GADA explain the association between family history of type 1 diabetes and non-insulin-dependent diabetes. This is supported by the fact that the effect of family history of type 1 diabetes on risk of diabetes was independent of GADA and that the genetic background of type 1 diabetes and GADA differs (2, 14, 15) . Alternatively, the association might be due to shared environmental factors.
Among initially nondiabetic adults, subjects with a high genetic risk score were unable to increase insulin secretion to the same level as subjects with a low score in response to reduced insulin sensitivity at the followup. This tendency is similar in carriers of multiple type 2 diabetes risk variants (34) . Together with a previous observation of association of GADA with decreased maximum insulin secretory capacity (10), our results support the notion that GADA and these susceptibility variants signify a compromised ability to increase insulin secretion, which does not invariably progress to diabetes. Of note, the statistical significance of this analysis was weak and considering the number of tests carried out these results require replication in a larger study sample. However, the observed effects are in line with the a priori hypothesis that type 1 diabetes susceptibility variants would affect insulin secretion.
In conclusion, type 1 diabetes susceptibility variants affected insulin secretion and PTPN22 CT/TT and HLA-DQ2.5/HLA-DQ8 genotypes were associated with GADA in nondiabetic adults. However, the investigated variants did not explain the association between family history of type 1 diabetes and development of non-insulin-dependent diabetes.
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